Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

EQRx Gives up on In-licensing Drugs from China for Lower Cost Therapies in the West

publication date: May 9, 2023

EQRx, a Cambridge, MA company, will change its business plan; the company will no longer in-license China-developed drugs for western markets, hoping to sell them at up to a 50% discount from the competition. EQRx will return rights to CStone Pharma for sugemalimab (a PD-L1 candidate) and nofazinlimab (a PD-1 antibody), and it will also give back rights to a JAK1 inhibitor from Lynk Pharmaceuticals. The company’s business plan may have become infeasible when the US FDA refused to approve a China-developed PD-1 drug based only on China trial data. Lilly acquired the candidate from Suzhou Innovent. More details....

Stock Symbol: (NSDQ: EQRX)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital